Infection and contamination control products supplier Tristel has strengthened its cash position with a corporation tax cash refund of £350,000. The refund comes after the company made a retrospective research and development tax claim. As a consequence of the tax relief the corporation tax accounts charge for the financial years 2010-11 and 2011-12 will be lower than previously anticipated, which as a result will improve earnings per share. In other news, following the company's announcement in June that it has received regulatory approval for the Tristel Wipes System from the Therapeutic Goods Association (TGA), the body that regulates disinfectant use in Australia, Tristel is appointing two distributors to serve the Australian market. AshMed will distribute the Wipes System into the urology and ear, nose and throat markets. Scanmedics will distribute the Wipes System into the hospital ultrasound market and is also the distributor for Australia for BK Medical's ultrasound products. House broker finnCap welcomed the announcements."A retrospective R&D tax credit reduces the effective tax rate for the year ending June 2011 and the current financial year; we assume an effective tax rate of 15%," finnCap analyst Keith Redpath said."Following the recentAustralian approval of the Tristel Wipes System, two distributors are appointed. Consequently, we increase our earnings forecasts for 2011 and2012," Redpath added.The 2011 earnings per share (EPS) forecast is reivsed to 2.19p from 2.00p previously, while the 2012 EPS forecast is now 3.28p, up from 2.95p before. The share price was up 7.96% to 42.00p at 14:01. NR